The trap is that vision feels fine right up until it doesn't. Glaucoma kills the nerve cells at the edges of your sight; you don't notice, because the good eye covers for the bad one and the center stays sharp until late. Macular degeneration starts as tiny yellow deposits under the retina that only a dilated pupil reveals. Early diabetic retinopathy is microscopic bleeds a doctor sees and you can't. Acuity, the number on your license, is the last thing these diseases touch.
The treatments are strongly proven, and all of them work only on tissue that's still alive. Lowering eye pressure roughly halves the odds of glaucoma taking hold 1 and cuts further nerve damage about in half once it starts 2. Antioxidant-plus-zinc supplements cut the progression of intermediate macular degeneration to advanced disease by a quarter 3. Laser cut severe vision loss from advanced diabetic disease by roughly 60% 4. Every one of these preserves what's there and restores nothing, so finding the disease early is the whole game.
Book the right kind of exam, and say so out loud.
Some people belong in the chair before 40. A parent or sibling with glaucoma roughly quadruples your risk; start in your 30s. African ancestry carries glaucoma four to five times more often, so screen on shorter intervals 7. Diabetes means an exam at diagnosis and yearly after 6. High myopia and any prior eye surgery mean a dilated exam at any age, because sharp vision tells you nothing about the retina underneath.
Most likely, you walk out with a clean exam and a reading-glasses prescription you'd been quietly needing, since about 85% of adults over 45 have that stiff-lens near blur 8. That's the working case. What you also get is the record: your normal optic-nerve photo, your normal pressure, your normal retinal scan. It changes nothing this year. But the exam you have at 52, when something looks slightly off, is a different exam when there's a clean image from 40 to compare it against.
The fine print — when to skip it, and what people get wrong
"I can see fine." The dangerous three are silent in the treatable window; good acuity is the last signal to fail. "A vision check at the mall counts." A refraction gives a glasses number; it skips dilation, pressure, and the retina. "LASIK fixed my eyes." It reshaped the cornea and did nothing for the nerve, retina, or macula.
Not urgent for everyone: average-risk adults with no symptoms and no family history can reasonably start the clock at 40. The task force found no trial proving screen-at-40 beats wait-for-symptoms, and calls the evidence insufficient either way 9. The treatment trials are not in doubt.
- 1Kass MA, Heuer DK, Higginbotham EJ, et al. (2002). The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. link
- 2Heijl A, Leske MC, Bengtsson B, et al. (2002). Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. link
- 3Age-Related Eye Disease Study Research Group (2001). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Archives of Ophthalmology. link
- 4The Diabetic Retinopathy Study Research Group (1981). Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. link
- 5Feder RS, Olsen TW, Prum BE, et al. (2020). Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern. Ophthalmology. link
- 6American Diabetes Association Professional Practice Committee (2025). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025. Diabetes Care. link
- 7American Academy of Ophthalmology (2015). Frequency of Ocular Examinations — Clinical Statement. link
- 8Holden BA, Fricke TR, Ho SM, et al. (2008). Global vision impairment due to uncorrected presbyopia. Archives of Ophthalmology. link
- 9US Preventive Services Task Force (2022). Screening for Primary Open-Angle Glaucoma: US Preventive Services Task Force Recommendation Statement. JAMA. link
დაკავშირებული სახელმძღვანელოში (9)
- — Glaucoma is one of the silent diseases this baseline exam is built to catch before you'd ever notice vision loss.
- — The grid catches macular changes at home; the dilated exam at 40 is the baseline it builds on.
- — Fold this into the once-a-year stack of preventive visits instead of treating it as a separate errand you'll forget.
- — Lens wearers should keep up regular eye exams — the eye doctor catches problems before they scar.
- — Different trigger, same idea: diabetes means yearly dilated exams regardless of age.
- — An eye exam is where AMD risk gets spotted — the trigger to take these pigments seriously.
- — The same 40s eye exam that catches silent disease is when presbyopia usually gets named.
- — Knowing your normal from a routine dilated exam makes it easier to recognise when new flashes or floaters are the real thing.
- — Years of UV is a driver of the cataracts the baseline exam is built to catch early.
Baseline Eye Exam at 40
A baseline comprehensive eye examination costs ~$100-$250 out of pocket in the US; many commercial vision plans cover it. Follow-ups every 2-4 years through age 54 per AAO PPP keep annualized cost under $50 in the typical case. Medicare covers diabetes- and glaucoma-risk evaluations (AAO 2020 PPP).
A single 60-90 minute appointment with 4-6 hours of post-dilation light sensitivity and accommodative blur. Sub-yearly cadence in the asymptomatic adult. No ongoing behaviour change required.
Meaningful disease prevention through early detection. The downstream-treatment RCTs are not in dispute: OHTS showed topical IOP-lowering halved 5-year glaucoma conversion (9.5% to 4.4%) (Kass et al. 2002); EMGT showed IOP-lowering halved progression in newly detected disease (HR 0.53) (Heijl et al. 2002); AREDS/AREDS2 reduced advanced-AMD progression 25% in intermediate disease (AREDS 2001; AREDS2 2013). Vision preservation compounds into reduced falls and dependence in later decades. Not a mortality intervention per se; the score reflects the disease-prevention end of the dimension.
Strong specialty-society consensus (AAO PPP, AOA, ADA) and robust RCT evidence on every downstream treatment (OHTS, EMGT, AREDS, AREDS2, DRS). But the screening leg itself — exam at 40 vs reactive care, with patient-relevant outcomes — has no direct RCT. The 2022 USPSTF systematic review (83 studies) issued an 'I' for glaucoma screening on insufficient-evidence grounds (USPSTF 2022). Strength of the recommendation reflects the gap between treatment-RCT certainty and screening-RCT absence.
For the subset whose baseline surfaces presbyopia (the modal finding at 40), a corrected near prescription restores function within days — reading, screens, menus. For the asymptomatic majority, no felt change. The score reflects the population-weighted shift, dominated by presbyopia detection (83-89% prevalence by mid-40s) (Holden et al. 2008).